In hormone receptor-positive BC patients, which account for the 70% of total BC3, one of the mainstays of treatment is the Adjuvant Hormone Therapy (AHT), which either suppresses hormone production (aromatase inhibitors such as Letrozole, Anastrozole and Exemestane) or interferes with hormone receptor signalling (Selective Estrogen Receptor Modulators such as Tamoxifen)4. Here, NR4A1 is linked to breast cancer.